No trading action warranted. This is a standard annual meeting proxy filing with no earnings, guidance, or material corporate developments. Monitor for Phase 2 clinical data readouts for SAT-3247 in Duchenne muscular dystrophy as the next potential catalyst.
Price Chart
Executive Summary
Satellos Bioscience Inc. filed its management information circular and proxy materials for the June 17, 2026 annual general meeting. The filing covers routine matters: election of nine director nominees, appointment of PricewaterhouseCoopers as auditors, and receipt of FY2025 audited financial statements. No material financial data, business updates, or strategic changes are disclosed — this is a standard annual meeting solicitation with no actionable trading implications.
Key Facts
- Annual general meeting scheduled for June 17, 2026, in virtual-only format
- Shareholders to vote on election of 9 director nominees and appointment of PwC as auditors
- As of May 14, 2026, 20,831,190 common shares outstanding (post-12:1 consolidation on Jan 27, 2026)
- No 10%+ beneficial holders identified
- Equity Incentive Plan has 358,116 shares available for future grants (~1.7% of outstanding)
- FY2025 audited financial statements to be presented but no shareholder vote required
Financial Impact
No financial impact — routine proxy solicitation with no material business or financial disclosures
Risk Factors
- No material risks disclosed beyond standard forward-looking statement cautionary language
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003561 |
| Exhibit: exh_993.htm | 0001171843-26-003561 |
| Exhibit: exh_992.htm | 0001171843-26-003561 |
| Exhibit: exh_994.htm | 0001171843-26-003561 |
| Document: f6k_051926.htm | 0001171843-26-003561 |
| Document: 0001171843-26-003561-index-headers.html | 0001171843-26-003561 |
| Document: 0001171843-26-003561-index.html | 0001171843-26-003561 |
| Document: 0001171843-26-003561.txt | 0001171843-26-003561 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers